Cancer Venous Thromboembolism (VTE)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1046 participants.
Also called NCT02073682
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,046 participants
- Sponsor
- Registry
-
NCT02073682 -
2014-004708-30
-
- Other papers using this trial's data
- Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
- Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, France, Hungary, Italy, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT02073682. Randomized; no masking; primary purpose treatment. Start 2015-07-16 (actual); primary completion 2017-09-15 (actual). Results posted on 2018-10-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cancer Venous Thromboembolism (VTE)
- Condition
- Venous Thromboembolism (VTE)
- Condition
- Deep Vein Thrombosis (DVT (deep vein thrombosis))
- Condition
- Pulmonary Embolism (PE)
- Condition
- Cancer
- Intervention (Drug)
- Edoxaban
- Intervention (Drug)
- Dalteparin
- Intervention (Drug)
- Low molecular weight heparin
- Lead sponsor
- Daiichi Sankyo
Record details
- Record id
cardio:ct-nct02073682- Content hash
19fce2a88bba781e92f8bbca3b3b5a342a3c44ebede83201be328fd31202c903